Australia's most trusted
source of pharma news
Wednesday, 22 July 2026
Posted 1 September 2025 PM
Receiving the shingles vaccination could lower the risk of heart attack and stroke, according to a meta-analysis conducted by GSK.
The study showed both the recombinant herpes zoster vaccine (RZV) and the live attenuated zoster vaccine (ZVL) were associated with a reduction in risk of cardiovascular events in adults aged 18-50 years or older, 18 per cent in the case of RZV and 16 per cent in the case of ZVL.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.